Interview with Ronald Christie, VP Interntaional Operations – General…
We found a Capital Markets Day presentation from Novo Nordisk that talked about the “rule of halves” – that of all people with diabetes, 50% of diagnosed, and of those…
Address: East Third Ring Road, Chaoyang District, Beijing No. 1 World Financial Center, East Building 18 Zip Code: 100020
Tel: +86 (010) 59615858
Web: http://www.novonordisk.com.cn/documents/home_page/document/index.asp
Novo Nordisk’s products were introduced to the Chinese market as early as the 1960s. In 1994 Novo Nordisk decided to invest in China by setting up Novo Nordisk (Tianjin) Biotechnology Co., Ltd., which was later renamed Novo Nordisk (China) Pharmaceuticals Co., Ltd.
Headquartered in Beijing, Novo Nordisk now employs more than 1,700 employees and has:
• regional offices in Shanghai, Guangzhou, Wuhan, Shenyang, Jinan and Hong Kong,
• production facilities in Tianjin
• a R&D center in Beijing.
Step by step, Novo Nordisk has become the leader in diabetes in China, with a complete organization covering R&D, production, sales and distribution networks.
While providing all major diabetes treatment products and comprehensive diabetes care to people with diabetes in China, Novo Nordisk is also committed to China’s environment and society and has launched social programs such as for example the NovoCare Bus, the NovoCare Club and the “NovoCare Sunshine Program” in Xinjiang, which is an insulin donation program in an earthquake-ravaged area.
R & D, diabetes treatment products, haemostasis management, hormone replacement therapy
We found a Capital Markets Day presentation from Novo Nordisk that talked about the “rule of halves” – that of all people with diabetes, 50% of diagnosed, and of those…
With nearly half of Chinese adults now suffering from myopia and age-related eye conditions on the rise, China is on the brink of an ophthalmology boom — a market set…
A summary of top stories from China’s pharma industry: Sciwind Biosciences presents promising trial data for its obesity contender; Simcere reaches approval for its Idorsia-partnered insomnia therapy; AstraZeneca inks AI-enabled…
Swapping the predictability of venture capital for the high-stakes volatility of biotech entrepreneurship, John Zhu set out to build something few in China had dared: a globally oriented biopharma with…
Ye Liu, CEO and cofounder of OcuMension Therapeutics, speaks about the challenges and triumphs of running one of China’s most ambitious ophthalmology-focused biopharmaceutical companies. Launched with USD 5 million and…
Building a biotech from the ground up is rarely the next step for someone who has led multinational pharmaceutical giants. Yet that was the challenge Pony Lu accepted when he…
2024 marks a moment of inflection for Harbour BioMed, as the company collect the rewards of a strong global execution. In this interview, Dr Jingsong Wang reflects on the strategic,…
As a result of its ageing demographic, China has seen a sharp rise in Alzheimer’s Disease (AD). The country’s AD patients over 60 already total some ten million and as…
This week’s Asia healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers China’s USD 36.2bn in outbound licensing agreements, Henlius & EssexBio meeting Phase III endpoints, Organon acquiring US…
This week’s Asia healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers the AACR 2025 ADC pipeline list from China, Puhe out-licensing global rights of a PRMT5 inhibitor to…
2024 was another groundbreaking year for Chinese medicine approvals. Writing in the March 2025 edition of DIA’s Global Forum magazine, Juan Valencia S. and Angel Shao of PharmCube explain how…
Illumina has been swept into the trade conflict between the US and China. After the Trump administration declared a 10 percent tariff on Chinese goods in February, Beijing retaliated by…
A roundup of some of the biggest stories coming out of China’s pharma industry, including the news that AstraZeneca may be seeing the other side of country’s probes; the counter-sanction…
See our Cookie Privacy Policy Here
